Risk factors for male breast cancer

Area of Science:

• Oncology
• Genetics
• Endocrinology

Background:

• Male breast cancer (MBC) diagnosis and risk stratification pose significant challenges.
• Known risk factors like obesity and environmental exposures do not identify large high-risk cohorts.
• BRCA2 mutations and Klinefelter's syndrome (KS) represent key genetic risk groups, accounting for up to 15% of MBC cases.

Purpose of the Study:

• To review risk factors and identify high-risk cohorts for male breast cancer.
• To evaluate the potential for endocrine intervention, specifically tamoxifen, in MBC management.
• To assess the feasibility of prevention studies for male breast cancer.

Main Methods:

• Literature review of male breast cancer risk factors and identified high-risk populations.
• Analysis of tumor characteristics, noting the high prevalence of ER+ve tumors (>90%).
• Review of endocrine therapy options and patient compliance data for tamoxifen.

Main Results:

• No single risk factor effectively identifies a large group with a high absolute number of MBC cases.
• BRCA2 mutation carriers and individuals with Klinefelter's syndrome are significant high-risk cohorts.
• Male patients exhibit poor tolerance to tamoxifen due to side effects, impacting compliance.

Conclusions:

• Current risk factor identification for male breast cancer is insufficient for large-scale prevention studies.
• While endocrine therapy is theoretically logical for ER+ve MBC, tamoxifen's side effects limit its use in men.
• Meaningful prevention studies for male breast cancer are not currently feasible due to small absolute case numbers in identified groups.